NCT02839889

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Hospice of Henderson County, Inc. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if naloxegol can be used in the treatment of opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of a two week randomized double blind period followed by a two week open-label period.

Conditions

• Cancer
• Constipation
• Pain

Interventions

Type	Name	Description
DRUG	Naloxegol	Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
DRUG	Placebo	Placebo once daily for two weeks, followed by two week open-label period

Timeline

• Start date: 2016-09-01
• Primary completion: 2018-01-11
• Completion: 2018-01-11
• First posted: 2016-07-21
• Last updated: 2019-03-05
• Results posted: 2019-03-05

Locations

3 sites across 1 country: United States